BFC Planning’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$287K Sell
1,230
-138
-10% -$31.9K 0.01% 806
2026
Q2
$290K Buy
1,368
+386
+39% +$75.8K 0.01% 813
2026
Q1
$192K Sell
982
-115
-10% -$22.3K 0.01% 891
2025
Q4
$190K Sell
1,097
-34,385
-97% -$6.26M 0.01% 884
2025
Q3
$6.76M Sell
35,482
-1,435
-4% -$255K 0.49% 37
2025
Q2
$6.63M Sell
36,917
-230
-0.6% -$39.9K 0.52% 35
2025
Q1
$6.29M Sell
37,147
-833
-2% -$137K 0.55% 30
2024
Q4
$5.73M Buy
37,980
+1,135
+3% +$177K 0.48% 39
2024
Q3
$5.72M Buy
+36,845
New +$5.5M 0.5% 36

Other funds holding DGX

BFC Planning's DGX Position: Q3 2026 in Review

BFC Planning reduced its Quest Diagnostics (DGX) stake by 10% in Q3 2026, selling an estimated $31.9K and leaving 1,230 shares worth $287K. The position accounts for 0.01% of the portfolio, ranked #806.

BFC Planning first reported a position in DGX in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.76M in Q3 2025. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • BFC Planning held 1,230 shares of Quest Diagnostics worth $287K as of Q3 2026.
  • BFC Planning sold 138 Quest Diagnostics shares in Q3 2026, an estimated $31.9K.
  • Quest Diagnostics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #806 holding.
  • BFC Planning first reported a position in Quest Diagnostics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Quest Diagnostics position peaked at $6.76M in Q3 2025.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.